NAMI Pharma Marketing Blog Grassley
View PDF of blog article here
Similar Posts
Protecting People w Mental Disabilities & Impairments against Biomedical Research Abuse
Protecting People with Mental Disabilities and Impairments against Biomedical Research Abuse[*] By John H. Noble, Jr., Ph.D, The Catholic University of America, Washington, DC, USA Vera Hassner Sharav, MLS, Alliance for Human Research Protection, New York, USA People with mental disabilities and impairments historically have been targeted by biomedical researchers…
US Inspector General Report: Antipsychotic Drug Hazards
An audit by Daniel Levinson, Inspector General of DHHS, confirms what has already been documented: that antipsychotics are widely misprescribed for unapproved uses and taxpayers are saddled with the high cost through Medicaid and Medicare.
The Crawford Resignation Mystery
The Crawford Resignation Mystery Sat, 24 Sep 2005 Merrill Goozner of Center for Science in the Public Interest provides insight into what may lie behind the sudden resignation of FDA Commissioner, Lester Crawford. Goozner surggests, “One possible clue to the administration’s thinking comes from the appointment of Andrew von Eschenbach,…
US Federal Judge Orders Wyeth Documents Unsealed
A U.S. federal judge has issued an order to unseal thousands of Wyeth Pharmaceutical documents that provide details about the company’s "mammoth" ghostwriting campaign.
Antipsychotic Use in Children: FDA Panel Rejects FDA Soft-Peddle Approach
"The committee’s concerns are part of a growing chorus of complaints about the increasing use of antipsychotic medicines in children and teenagers.
Despite Vow, Drug Makers Still Wtihhold Data – NYT letters
Despite Vow, Drug Makers Still Wtihhold Data – NYT letters Thu, 9 Jun 2005 An important article by Alex Berenson in The New York Times, “Despite Vow, Drug Makers Still Withhold Data,” corroborated the untrustworthiness of drug manufacturers. Their public pronouncements and promises to fully disclose their clinical trial data-including…